SpringerLink
Log in

Thioxanthene

  • Chapter
Neuro-Psychopharmaka Ein Therapie-Handbuch

  • 46 Accesses

Zusammenfassung

Für Thioxanthene (Clopenthixol, Chlorprothixen, Flupentixol, Thiothixen, Zuclopenthixol) stehen verschiedene Arzneimittelformen als intravenöse oder orale Darreichungsformen und Depotzubereitungen zur Verfügung. Nach oraler Applikation werden die Thioxanthene nahezu vollständig resorbiert, aber aufgrund der ausgeprägten präsystemischen Elimination während der ersten Leberpassage fällt die orale Bioverfügbarkeit sehr gering aus. Im systemischen Kreislauf verteilt sich der Wirkstoff rasch mit dem Blut im Organismus. Thioxanthene sind lipophile Substanzen und kommen im Blut überwiegend an Plasmaproteine gebunden vor, bzw. sie verteilen sich im gesamten Organismus und reichern sich im Gewebe und in Membranen an. Auch bei den Thioxanthenen ist die Pharmakokinetik aus den bereits bei den Phenothiazinen genannten Gründen nicht hinreichend untersucht.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 119.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Aaes-Jørgensen T (1981) Serum concentrations of cis(Z)-and trans(E)-clopenthixol after administration of cis(Z)-clopentixol and clopenthi-xol to human volunteers. Acta Psychiatr Scand [Suppl] 294: 64–69

    Google Scholar 

  • Aaes-Jørgensen T (1989) Pharmacokinetics of three different injectable zuclopenthixol preparations. Prog Neuropsychopharmacol Biol Psychiatry 13: 77–85

    PubMed  Google Scholar 

  • Aaes-Jørgensen T, Gravem A, Jørgensen A (1981) Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)/ trans(E)-clopenthixol. Acta Psychiatr Scand [Suppl] 294: 70–77

    Google Scholar 

  • Aaes-Jørgensen T, Liedholm H, Melander A (1987) Influence of food intake on the bioavailability of zuclopenthixol. Drug-Nutrient Interactions 5: 157–160

    PubMed  Google Scholar 

  • Amdisen A, Aaes-Jørgensen T, Thomsen NJ, Madsen VT, Neilsen MS (1986) Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in Visoleo. Psychophar-macology 90: 412–416

    CAS  Google Scholar 

  • Bagli M (1996) Pharmakokinetik und Pharmakodynamik von Neuroleptika. Dissertation, Universität Bonn

    Google Scholar 

  • Bagli M, Rao ML, Höflich G (1994) Quantification of chlorprothixene, levomepromazine and promethazine in human serum using high-performance liquid chromatography with coulometric electrochemical detection. J Chrom 657: 141–148

    CAS  Google Scholar 

  • Bagli M, Rao ML, Höflich G, Kasper S, Langer M, Barlage U, Beneke M, Süverkrüp R, Möller HJ (1996a) Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. Drug Res 46: 247–250

    CAS  Google Scholar 

  • Bagli M, Süverkrüp R, Rao ML, Bode H (1996b) Mean input times of three oral chlorprothixene formulations assessed by an enhanced least-squares deconvolution method. J Phar-maceut Sci 85: 434–439

    CAS  Google Scholar 

  • Balant-Gorgia AE, Gex-Fabry M, Balant LP (1996) Therapeutic drug monitoring and drug-drug interactions: a pharmacoepidemiologi-cal perspective. Therapie 51: 399–402

    PubMed  CAS  Google Scholar 

  • Bergling R, Mjorndal T, Oreland L, Rapp W, Wold S (1975) Plasma levels and clinical effects of thioridazine and thiothixene. J Clin Pharmacol 15: 178

    PubMed  CAS  Google Scholar 

  • Breyer-Pfaff U, Wiest E, Prox A, Wachsmuth H, Protiva M (1985) Phenolic metabolites of chlorprothixene in man and dog. Drug Metab Dispos 13: 479–489

    PubMed  CAS  Google Scholar 

  • Brøsen K (1990) Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 18:220–239

    PubMed  Google Scholar 

  • Dahl ML, Ekqvist B, Widen J, Bertilsson L (1991) Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxy-lation of debrisoquin in humans. Acta Psychiatr Scand 84: 99–102

    PubMed  CAS  Google Scholar 

  • Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW (1991) Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 11: 296–301

    PubMed  CAS  Google Scholar 

  • Freedberg KA, Innis RB, Creese I, Snyder SH (1979) Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sci 24: 2467–2474

    PubMed  CAS  Google Scholar 

  • Gex-Fabry M, Balant-Gorgia AE, Balant LP (1997) Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication. Ther Drug Monit 19: 1–10

    PubMed  CAS  Google Scholar 

  • Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD (1974) Pharmacokinetics of thiothixene in man. Clin Pharmacol Ther 16: 473–478

    PubMed  CAS  Google Scholar 

  • Jørgensen A (1980) Phamacokinetic studies in volunteers of intravenous and oral cis(Z)-flu-penthixol and intramuscular cis(Z)-flupenthi-xol decanoate in Visoleo. Eur J Clin Pharm 18: 355–360

    Google Scholar 

  • Jørgensen A, Andersen J, Bjorndal N, Dencker SJ, Lundin L, Malm U (1982) Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupenti-xol and cis(Z)-flupentixol decanoate. Psycho-pharmacology Berl 77: 58–65

    Google Scholar 

  • Kivistö KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37: 40S–48S

    PubMed  Google Scholar 

  • Kjølbye M, Thomsen K, Rogne T, Rehfelt E, Olesen OV (1994) Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients. Ther Drug Monit 16: 541–547

    PubMed  Google Scholar 

  • Linnet K (1994) Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopenthixol with tricyclic antidepressives. Ther Drug Monit 17: 308–311

    Google Scholar 

  • Mavroidis ML, Kantor DR, Hirschowitz J (1984) Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol 4: 155–157

    PubMed  CAS  Google Scholar 

  • Poulsen JH, Olesen OV, Ursen NE (1993) Fluctuation of serum zuclopenthixol concentrations in patients treated with zuclopenthixol decanoate in viscoleo. Ther Drug Monit 16: 155–159

    Google Scholar 

  • Raaflaub J (1975) On the pharmacokinetics of chlorprothixene in man. Experentia 31: 557–558

    CAS  Google Scholar 

  • Soni SD, Sampath G, Shah A, Krska J (1992) Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Acta Psychiatr Scand 85: 354–359

    PubMed  CAS  Google Scholar 

  • Tuninger E, Levander S (1996) Large variations of plasma levels during maintance treatment with depot neuroleptics. Br J Psychiatry 169: 618–621

    PubMed  CAS  Google Scholar 

  • Yesavage JA, Holman CA, Cohn R (1981) Correlation of thiothixene serum levels and age. Psychopharmacol 74: 170–172

    CAS  Google Scholar 

  • Yesavage JA, Becker J, Werner PD, Mills MJ, Holman CA, Cohn R (1982) Serum level monitoring of thiothixene in schizophrenia: acute single-dose levels at fixed doses. Am J Psychiatry 139: 174–178

    PubMed  CAS  Google Scholar 

  • Yesavage JA, Holman CA, Cohn R, Lombrozo L (1983) Correlation of initial thiothixene serum levels and clinical response. Comparison of fluorometric, gas chromatographic, and RBC assays. Arch Gen Psychiatry 40: 301–304

    PubMed  CAS  Google Scholar 

Literatur

  • Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51: 321–329

    CAS  Google Scholar 

  • Arnt J (1983) Neuroleptic inhibition by 6,7-ADTN-induced hyperactivity after injection into the nucleus accumbens. Specificity and comparison with older models. Eur J Pharmacol 90: 47–55

    PubMed  CAS  Google Scholar 

  • Arnt J (1985) Antistereotypic effects of dopamine D1-and D2-antagonists after intrastriatal injection in rats. Pharmacological and regional specificity. Naunyn Schmiedebergs Arch Pharmacol 330: 97–104

    PubMed  CAS  Google Scholar 

  • Arnt J, Hyttel J (1986) Inhibition of SKF 38393-and pergolide-induced circling in rats with unilateral 6-OHDA lesions is correlated to dopamine D1-and D2-receptor affinities in vitro. J Neural Transm 67: 225–240

    PubMed  CAS  Google Scholar 

  • Arnt J, Hyttel J, Larsen JJ (1984) The Citalopram/ 5-HTP-induced head shake syndrome is correlated to 5-HT2 receptor affinity and also influenced by other transmitters. Acta Pharmacol Toxicol 55: 363–372

    CAS  Google Scholar 

  • Dunn LA, Atwater GE, Kilts CD (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharma-col 112: 315–323

    CAS  Google Scholar 

  • Fjalland B, Boeck V (1978) Neuroleptic blockade of various neurotransmitter substances. Acta Pharmacol Toxicol 42: 206–211

    CAS  Google Scholar 

  • Hyttel J (1985) Dopamine D1 and D2-receptors. Characterization and differential effects of neuroleptics. In: Dahlbaum R, Nilsson JLG (eds) Proceedings of the VIIIth international symposium on medicinal chemistry, vol 1. Acta Pharm Suecica [Suppl 1]: 426–439

    Google Scholar 

  • Hyttel J, Arnt J (1987) Characterization of binding of 3H-SCH 23390 to dopamine D1-recep-tors. Correlation to other D1-and D2-measures and effect of selective lesions. J Neural Transm 68: 171–189

    PubMed  CAS  Google Scholar 

  • Hyttel J, Arnt J, van den Berghe M (1989) Selective dopamine D1-and D2-receptor antagonists. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 109–122

    Google Scholar 

  • Killcross AS, Dickinson A, Robbins TW (1994) Effects of the neuroleptic alpha-flupenthixol/ on latent inhibition in aversively-and appet-itively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psycho-pharmacol 115: 196–205

    CAS  Google Scholar 

  • Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2-receptors. Psychopharmacol 112: S40–S54

    CAS  Google Scholar 

  • Møller-Nielsen I, Pedersen V, Nymark M, Franck KF, Boeck V, Fjalland B, Christensen AV (1973) The comparative pharmacology of flupenthixol and some reference neuroleptics. Acta Pharmacol Toxicol 33: 353–362

    Google Scholar 

  • Petersen PV, Lassen N, Holm T, Kopf R, Møller-Nielsen I (1958) Chemische Konstitution und pharmakologische Wirkung einiger Thioxan-then-Analoge zu Chlorpromazin, Promazin und Mepazin. Arzneimittelforschung 8: 395–397

    PubMed  CAS  Google Scholar 

  • Rigdon GC, Viik K (1991) Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev Res 23: 91–99

    CAS  Google Scholar 

  • Skarsfeldt T, Amdt J, Hyttel J (1990) L-5-HTP facilitates the electrically stimulated flexor reflex in pithed rats: evidence for 5-HT2-receptor mediation. Eur J Pharmacol 176: 135–142

    PubMed  CAS  Google Scholar 

  • Svendsen O, Arnt J, Boeck V, Bøgesø KP, Christensen AV, Hyttel J, Larsen JJ (1986) The neu-ropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects. Drug Dev Res 7: 35–47

    CAS  Google Scholar 

  • Testa R, Abbiati G, Ceserani R, Restelli G, Vanasia A, Barone D, Gobbi M, Mennini T (1989) Profile of in vitro binding affinities of neuroleptics at different rat brain receptors: cluster analysis comparison with pharmacological and clinical profiles. Pharm Res 6: 571–577

    PubMed  CAS  Google Scholar 

Literatur

  • Aaes-Jørgenson T, Wistedt B, Koskinen T, The-Lander S et al. (1991) Zuclopenthixol de-canoate and haloperidol decanoate in chronic schizophrenia. Serum levels during maintenance treatment. Psychopharmacol 103: 14

    Google Scholar 

  • Ahlfors UG, Dencker SJ, Gravem A, Remvig J (1980) Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. Acta Psychiatr Scand 61: 77–91

    Google Scholar 

  • Amidsen A, Aaes-Jørgensen T, Thomsen HJ, Mad-Sen VT, Nielsen MS (1986) Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixolacetate in viscoleo. Psy-chopharmacology 90: 412–416

    Google Scholar 

  • Baastrup PC, Alhfors UG, Bjerkenstedt L, Dencker SJ et al. (1993) A controlled Nordic multi-center study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatr Scand 87: 48–58

    PubMed  CAS  Google Scholar 

  • Bandelow B, Müller P, Gaebel W, Linden M et al. (1992) Depressive syndromes in schizophrenic patients under neuroleptic therapy. Eur Arch Psychiatry Clin Neurosci 241: 291–295

    PubMed  CAS  Google Scholar 

  • Bjerum H, Allerup P, Thunedborg K, Jakobsen K et al. (1992) Treatment of generalized anxiety disorder: comparison of a new beta-blocking drug (CGP-361-A), low-dose neuroleptic (Flu-pentixol) and placebo. Pharmacopsychiatry 25: 229–232

    Google Scholar 

  • Bobon D, Debleeker E (1989) Zuclopenthixol acetate and haloperidol in acute psychotic patients. A randomized multicentre study. ECNP Congress, Gothenburg

    Google Scholar 

  • Bradley PB, Hirsch SR (1986) The psychophar-macological and somatic treatment of schizophrenia. Oxford University Press

    Google Scholar 

  • Budde G (1992) Efficacy and tolerability of flu-penthixol decanoate in the treatment of depression and psychosomatic disorder: a multicentre trial. Prog Neuropsychopharmacol Biol Psychiatry 16: 677–689

    PubMed  CAS  Google Scholar 

  • Carney MWP, Sheffield BF (1973) The long-term maintenance treatment of schizophrenic outpatients with depot flupenthixol. Curr Med Res Opin 1: 423

    PubMed  CAS  Google Scholar 

  • Cesarec Z, Eberhard G, Nordgren L (1974) A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. Acta Psychiatr Scand 249: 65–77

    CAS  Google Scholar 

  • Chouinard G, Safadi G, Beauclair L (1994) A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 16: 377–384

    Google Scholar 

  • Chowdhury MEH, Chacon C (1980) Depotfluphe-nazine and flupenthixol in the treatment of stabilized schizophrenics: a double-blind comparative trial. Compr Psychiatry 21:135–139

    PubMed  CAS  Google Scholar 

  • Cold JA, Wells BG, Froemming JJ (1990) Seizures activity associated with antipsychotic therapy. Ann Psychother 24: 601–606

    CAS  Google Scholar 

  • Cotes MP, Crow TJ, Johnstone EC, Bartlett W et al. (1978) Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychol Med Lond 8: 657–665

    CAS  Google Scholar 

  • Davis JM, Casper R (1978) Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 14: 260–282

    Google Scholar 

  • Dehnel LL, Vestre ND, Schiele BC (1968) A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population. Curr Ther Res 10: 169–176

    PubMed  CAS  Google Scholar 

  • Dencker SJ, Malm UA, Joergensen A, Overoe KF (1980) Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. Acta Psychiatr Scand 61[Suppl 279]: 55–63

    Google Scholar 

  • Eberhard G, Hellbom E (1986) Haloperidol deca-noate and flupenthixol decanoate in schizophrenia. A long-term double blind cross-over comparison. Acta Psychiatr Scand 74: 255–262

    PubMed  CAS  Google Scholar 

  • Fabian JL (1993) Psychotropic medications and priapism. Am J Psychiatry 150: 349–350

    PubMed  CAS  Google Scholar 

  • Fensbo C (1990) Zuclopenthixolacetate, ha-loperidol and zuclopenthixol in the treatment of acutely psychotic patients — a controlled multicenter study. Nord Psykiatr Tidsskr 44: 295–297

    Google Scholar 

  • Fuglum E, Schillinger A, Andersen JB et al. (1989) Zuclopenthixol and haloperidol/levomepro-mazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind multicentre study. Phar-matherapeutica 5: 285–291

    CAS  Google Scholar 

  • Gawin FH, Allen D, Humblestone B (1989) Outpatient treatment of „crack“ cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 46: 322–325

    PubMed  CAS  Google Scholar 

  • Gerlach J, Kramp P, Kristjansen P, Lauritsen B et al. (1975) Peroral and parenteral administration of longacting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. Acta Psychiatr Scand 52: 132

    PubMed  CAS  Google Scholar 

  • Götesstam KG, Ljunghall S, Olsson B (1981) A double-blind comparison of the effects of haloperidol and cis (Zuclopenthixol in senile dementia. Acta Psychiatr Scand [Suppl 294] 64: 46–53

    Google Scholar 

  • Gouliaev G, Licht RW, Vestergaard P, Merinder L et al. (1996) Treatment of manic episodes: zuclopenthixol and clonazepam versus lithium and clonazepam. Acta Psychiatr Scand 93: 199–242

    Google Scholar 

  • Gravem A, Elgen K (1981) Cis (Z)-clopenthixol. The neuroleptically active isomers of clopenthixol. A presentation of five double-blind clinical investigations and other studies with cis (Z)-clopenthixol (Cisordinol, Clopixol). Acta Psychiatr Scand [Suppl 294] 64: 5–12

    Google Scholar 

  • Grohmann R, Rüther E, Schmidt LG (Hrsg) (1994) Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Gruber AJ, Cole JO (1991) Antidepressant effects of flupentixol. Pharmacotherapy 11: 450–459

    PubMed  CAS  Google Scholar 

  • Harenko A, Alanen I, Elovaara S, Ginstrom S et al. (1992) Zuclopenthixol and thioridazine in the treatment of aggressive, elderly patients: a double-blind, controlled multicentre study. Int J Geriatr Psychiatry 7: 369–375

    Google Scholar 

  • Haslam MT, Bromham BM, Schiff AA (1975) A comparative trial of fluphenazine decanoate and flupenthixol decanoate. Acta Psychiatr Scand 51: 92–100

    PubMed  CAS  Google Scholar 

  • Heikkilä L, Laitinen J, Vartiainen H (1981) Cis (Z)-clopenthixol and haloperidol in chronic schizophrenic patients — a double-blind clinical multicenter investigation. Acta Psychiatr Scand [Suppl 294] 64: 30–38

    Google Scholar 

  • Heikkilae L, Eliander H, Vartiainen H et al. (1992) Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study. Curr Med Res Opin 12: 594–603

    Google Scholar 

  • Huttunen MO, Piepponen T, Rantanen H, Larmo I et al. (1995) Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 91: 217–277

    Google Scholar 

  • Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10: 315–333

    PubMed  CAS  Google Scholar 

  • Johnson DA, Malik NA (1975) A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatr Scand 51: 257–267

    PubMed  CAS  Google Scholar 

  • Jørgensen A, Aaes-Jørgensen T, Gravem A, Amthor KF et al. (1987) Zuclopenthixolde-canoate in schizophrenia: serum levels and clinical state. Psychopharmacology 87: 364–367

    Google Scholar 

  • Karsten D, Kivimäki T, Linna SL, Pollari L, Tturunen S (1981) Neuroleptic treatment of oligophrenic patients. A double-clinical multicenter trial of cis (Z)-clopenthixol and haloperidol. Acta Psychiatr Scand [Suppl 294] 64: 39–45

    Google Scholar 

  • Kelly HB, Freeman HL, Banning B, Schiff AA (1977) Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. Int Pharmacopsy-chiat 12: 54–70

    CAS  Google Scholar 

  • Kemperman CJF (1989) Zuclopenthixol-induced neuroleptic malignant syndrome at rechallen-ge and its extrapyramidal effects. Br J Psychiatry 154: 562–563

    PubMed  CAS  Google Scholar 

  • Kissling W, Möller HJ, Bäuml J, Dietzfelbinger TH et al. (1990) Fluanxol Depot 10% versus Haloperidoldecanoat — Dosierung und Applikationsintervalle. In: Müller-Oerlinghausen B, Möller HJ, Rüther E (Hrsg) Thioxanthene. Springer, Berlin Heidelberg New York Tokyo, S 199–207

    Google Scholar 

  • Knights A, Okasha MS, Salih M, Hirsch SR (1979) Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic outpatients. Br J Psychiatry 135: 515–524

    PubMed  CAS  Google Scholar 

  • König P, Seifert TH, Eberhardt G (1986) Findings with cis-Z-clopenthixol in the treatment of acute mania and schizophrenia. Pharmaco-psychiat 19: 424–428

    Google Scholar 

  • Kutcher S, Papatheodorou G, Reiter S et al. (1995) The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial with flupenthixol. J Psychiatry Neu-rosci 20: 113–118

    CAS  Google Scholar 

  • Landa L, Breivik H, Husebo S et al. (1984) Beneficial effects of flupenthixol on cancer pain patients. Pain 2: 253

    Google Scholar 

  • Lowert AC, Rasmussen EM, Holm R et al. (1989) Acute psychotic disorders treated with 5% zuclopenthixol acetate in “Viscoleo”, a global assessment of clinical effect: an open multicentre study. Pharmatherapeutica 5: 380–386

    PubMed  CAS  Google Scholar 

  • Mair M, Schwitzer H, Nowak H, Schifferle L et al. (1985) Akutsedierung mit Zuclopenthixol-Acetat in Viscoleo bei Exazerbationen chronisch schizophrener Psychosen. Neuropsychiatrie 3: 32–35

    Google Scholar 

  • Malt UF, Nystad R, Bache T, Noren O et al. (1995) Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioral disturbanced in learning disabled patients. Br J Psychiatry 166: 374–377

    PubMed  CAS  Google Scholar 

  • Mann BS, Moslehuddin KS, Owen RT et al. (1985) A clinical assessment of zuclopenthixol di-hydrochloride in the treatment of psychotic illness. Pharmatherapeutica 4: 387–392

    PubMed  CAS  Google Scholar 

  • Mccreadie GR (1979) High dose flupenthixol decanoate in chronic schizophrenia. Br J Psychiatry 135: 175–179

    PubMed  CAS  Google Scholar 

  • Mccreadie GR, Wiles DH, Moore JW, Grant SM et al. (1987) The Scottish first episode schizophrenia study. 1. Patient identification and categorisation. 2. Treatment: Pimozide versus flupenthixol. 3. Cognitive performance. 4. Psychiatric and social impact on relatives. Br J Psychiatr 150: 331–344

    Google Scholar 

  • Müller-Oerlinghausen B, Möller H-J, Rüther E (Hrsg) (1990) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Müller-Spahn F, Dieterle D, Kurtz G, Rüther E (1990) Vergleichende Anwendung von cis(Z)-Clopenthixol und Haloperidol bei Patienten mit akuten schizophrenen Psychosen. In: Müller-Oerlinghausen B, Möller HJ, Rüther E (Hrsg) Thioxanthene. Springer, Berlin Heidelberg New York Tokyo, S 115–121

    Google Scholar 

  • Náhunek K, Sveszka J, Rodová A (1970) Comparison of the therapeutic effect of flupenthixol and perphenazine in schizophrenia. Activ Nerv Sup 12: 247–248

    Google Scholar 

  • Napolitano C, Priori SG, Schwartz PJ (1994) Torsade de pointes. Mechanisms and management. Drugs 47: 51–65

    PubMed  CAS  Google Scholar 

  • Nash O, Rydenhag A (1993) A case report. Torsades de pointes caused by overdose of thioridazine. Lakartidningen 90: 3677–3678, 3681

    PubMed  CAS  Google Scholar 

  • Nolden WA (1983) Dopamine and mania. The effects of trans-and cis-clopenthixol in a double-blind pilot study. J Affect Disord 5: 91–96

    Google Scholar 

  • Nygaard H, Bakke K, Brudvik E, Lien GK et al. (1987) Zuclopenthixol and melperon in the treatment of elderly patients: a double-blind, controlled, multi-center study. Pharmatherapeutica 5: 152–158

    Google Scholar 

  • Nygaard HA, Fuglum E, Elgen K (1992) Zuclopenthixol, melperone and haloperidol/lev-omepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway. Curr Med Res Opin 12: 615–622

    PubMed  CAS  Google Scholar 

  • Parent M, Toussaint C (1983) Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica 3: 354–364

    PubMed  CAS  Google Scholar 

  • Pinto R, Banjerjee A, Ghosh N (1979) A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatr Scand 60: 313–322

    PubMed  CAS  Google Scholar 

  • Pöldinger W, Sieberns S (1983) Depression-inducing and antidepressive effects of neuroleptics: experience with flupentixol and flupentixol decanoate. Depressiogene und antidepressive Wirkungen der Neuroleptika: Erfahrungen mit Flupentixol und Flupentixol Decanoat. Neuropsychobiology 10: 131–136

    PubMed  Google Scholar 

  • Porot M, Aubin B, Charbonnier et al. (1984) Etude multicentrique controllee du cis (Z)-clopenthixol centre haloperidol chez les patients schizophreniques. Act Psychiatr 14: 165–175

    Google Scholar 

  • Ravn J, Scharff A, Aaskoven O (1980) 20 Jahre Erfahrungen mit Chlorprothixen. Pharmako-psychiat 13: 34–40

    CAS  Google Scholar 

  • Remvtg J, Larsen H, Rask P, Skausig OB et al. (1987) Zuclopenthixol and perphenazine in patients with acute psychotic states. A double blind multicentre study. Pharmacopsychiat 20: 147–154

    Google Scholar 

  • Rimon R, Kampman R, Laru-Sompa R, Heikkilä L (1985) Serum and cerebrospinal fluid prolactin pattern during neuroleptic treatment in schizophrenic patients. Pharmacopsychiat 18: 252–254

    CAS  Google Scholar 

  • Saxena B, Maccrimmon D, Busse E, Syrotuik J et al. (1988) Clopenthixol decanoate and fluphena-zine decanoate in the maintenance treatment of chronic schizophrenia — a double-blind study. Psychopharmacology 96 [Suppl]: 205

    Google Scholar 

  • Silverstone T, Smith G, Goodall E (1988) Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 153: 214–217

    PubMed  CAS  Google Scholar 

  • Solgaard T, Kistrup K, Aaes-Jørgensen T, Gerlach J (1994) Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients. Minimum effective dose and corresponding serum levels. Pharmacopsychiat 27: 119–123

    CAS  Google Scholar 

  • Soyka M, Sand P (1995) Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry 28: 64–65

    PubMed  CAS  Google Scholar 

  • Tegeler J (1985) A comparative trial of CIS (Z)-clopenthixol-decanoate and fluphenazine-decanoate. Pharmacopsychiatry 18: 78–79

    Google Scholar 

  • Trimble MP, Robertson MM (1983) Flupenthixol in depression. A study of serum levels and prolactin response. J Affect Disord 5: 81–89

    PubMed  CAS  Google Scholar 

  • Trueman HR, Valentine MG (1974) Flupentixol decanoate in schizophrenia. Br J Psychiatry 124: 58

    PubMed  CAS  Google Scholar 

  • Turbott J, Smeeton WMI (1984) Sudden death and flupenthixol decanoate. Aust NZ J Psychiatry 18: 91–94

    CAS  Google Scholar 

  • Van Hemert AM, Meinhardt W, Moehadjir D, Kropman RF (1995) Recurrent priapism as a side effect of zuclopenthixol decanoate. Int Clin Psychopharmacol 10: 199–200

    PubMed  Google Scholar 

  • Wistedt B, Ranta J (1983) Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatr Scand 67: 378–388

    PubMed  CAS  Google Scholar 

  • Wistedt B, Koshinen T, Thelander S et al. (1991) Zuclopenthixoldecanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicenter study. Acta Psychiatr Scand 84: 14–21

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Bagli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. L. Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Fritze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. König
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Bezirkskrankenhaus Gabersee, Wasserburg/Inn, Bundesrepublik Deutschland

    Gerd Laux

  3. Wien, Österreich

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Wien

About this chapter

Cite this chapter

Bagli, M., Rao, M.L., Fritze, J., Laux, G., König, P. (1998). Thioxanthene. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6458-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6458-7_6

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-7327-5

  • Online ISBN: 978-3-7091-6458-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation